GSK962040 Drug-drug Interaction Study With Ketoconazole
Status:
Completed
Trial end date:
2009-11-30
Target enrollment:
Participant gender:
Summary
This study will determine the effect of 400 mg ketoconazole on the pharmacokinetics of a
single dose of GSK962040. The results from this study will help to estimate the maximum
increase in exposure during concomitant use of strong CYP3A4 inhibitors. This study will also
contain an exploratory investigation of biliary secretion of GSK962040 and or its
metabolites.